NICE reversal for osteoporosis

NICE has reversed its decision to recommend alendronate as the only treatment option for osteoporosis in post-menopausal women.

A draft appraisal document issued this week by NICE recommends second-line use of risedronate and etidronite in primary and secondary prevention of fractures.

The move comes after concerns that, following NICE's guidance in June to only prescribe alendronate, GPs are being forced by PCTs to prescribe the drug to patients with osteoporosis, despite one in four patients being unable to tolerate it (GP, 12 October 2007).

The U-turn by NICE is dependent on a patients' T-scores.

NICE Osteoporosis appraisal consultation document 2008

Comment below and tell us what you think  

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus